Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
KDM4C is a member of the Jumonji domain 2 (JMJD2) family and encodes a protein with one JmjC domain, one JmjN domain, two PHD-type zinc fingers, and two Tudor domains. Additionally we are shipping KDM4C Proteins (7) and many more products for this protein.
Showing 10 out of 59 products:
Human Polyclonal KDM4C Primary Antibody for EIA, FACS - ABIN952976
Suikki, Kujala, Tammela, van Weerden, Vessella, Visakorpi: Genetic alterations and changes in expression of histone demethylases in prostate cancer. in The Prostate 2010
Show all 2 references for ABIN952976
Human Polyclonal KDM4C Primary Antibody for EIA, WB - ABIN493083
Yi, Hao, Yang, Wang, Xing, Xu: cDNA cloning, bioinformatic and tissue-specific expression analysis of porcine JARID1C gene. in Journal of genetics and genomics = Yi chuan xue bao 2007
Show all 2 references for ABIN493083
Human Polyclonal KDM4C Primary Antibody for FACS, WB - ABIN655391
Liu, Bollig-Fischer, Kreike, van de Vijver, Abrams, Ethier, Yang: Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. in Oncogene 2009
Show all 2 references for ABIN655391
Human Polyclonal KDM4C Primary Antibody for WB - ABIN2777688
Lu, Ward, Kapoor, Rohle, Turcan, Abdel-Wahab, Edwards, Khanin, Figueroa, Melnick, Wellen, ORourke, Berger, Chan, Levine, Mellinghoff, Thompson: IDH mutation impairs histone demethylation and results in a block to cell differentiation. in Nature 2012
Histone demethylases KDM3A (show KDM3A Antibodies), KDM4A (show KDM4A Antibodies), and KDM4C were expressed before and after embryonic genome activation, whereas KDM5B (show KDM5B Antibodies) was mainly expressed during the blastocyst period.
KDM4C recognition of H3K4me3 stimulates demethylation of H3K9me3 in cis (show CISH Antibodies) on peptide and mononucleosome substrates.
Pharmacological inhibition of KDM4C/PRMT1 (show PRMT1 Antibodies) suppresses transcription and transformation ability of MLL (show MLL Antibodies) fusions
JMJD2B (show KDM4B Antibodies) and JMJD2C play an important role in the pathology of osteosarcoma via the up-regulation of FGF2 (show FGF2 Antibodies).
Data suggest that D396N polymorphism of JmjC domain-containing histone demethylase (show MBD2 Antibodies) JMJD2C affects the prognosis of breast cancer by altering caspase-3 (show CASP3 Antibodies) cleavage and the ability of double strand DNA break repair which may contribute to therapy resistance.
GASC1 expression is higher in adenocarcinoma than squamous cell carcinoma. Smoking decreases GASC1 expression in tumor cells, indicating that tobacco smoke may influence the methylation of histone 3 lysine residues in lung cancer.
KDM4C promotes transcriptional activation by removing the repressive histone mark, H3K9me3, from its target genes. Variation in its expression leads to differences in the growth of normal and some cancer cells.
KDM4C maintains the sphere-forming capacity in CRCs by mediating the beta-catenin (show CTNNB1 Antibodies)-dependent transcription of JAG1 (show JAG1 Antibodies) in a feed-forward manner.
analysis of the nickel-induced inhibition of truncated constructs of JMJD2A (show KDM4A Antibodies) and JMJD2C histone demethylases using X-ray absorption spectroscopy
Patients with GASC1 positive tumors have better breast cancer specific survival and respond better to radiotherapy and hormonal treatment
JMJD2C decreases trimethylation of histone H3 (show HIST3H3 Antibodies) at lysine 9, and enhances HIF-1 (show HIF1A Antibodies) binding to hypoxia response elements, thereby activating transcription of proteins that are required for metabolic reprogramming and for lung metastasis.
GASC1 has an oncogenic role in mouse skin carcinogenesis.
These findings together demonstrate the essential role of KDM4A (show KDM4A Antibodies) and KDM4C in orchestrating mESC differentiation to endothelial cells through the activation of Flk1 (show KDR Antibodies) and VE-cadherin (show CDH5 Antibodies) promoters, respectively
Jmjd2C increases MyoD (show MYOD1 Antibodies) transcriptional activity to facilitate skeletal muscle differentiation by increasing MyoD (show MYOD1 Antibodies) stability through inhibiting G9a (show EHMT2 Antibodies)-dependent MyoD (show MYOD1 Antibodies) degradation.
Jmjd2b (show KDM4B Antibodies) unique, Jmjd2c unique, and Jmjd2b (show KDM4B Antibodies)-Jmjd2c common target sites belong to functionally separable Core, Polycomb (show CBX2 Antibodies) repressive complex (PRC (show PPRC1 Antibodies)), and Myc (show MYC Antibodies) regulatory modules, respectively.
Inositol pyrophosphates regulate JMJD2C-dependent histone demethylation.
stage-specifically expressed during preimplantation development (show MTA2 Antibodies), with the highest activity being observed from the two-cell to the eight-cell stage
Jmjd2c acts as a positive regulator for Nanog, which encodes for a key transcription factor for self-renewal in ES cells.
These results indicate that Mdm2 (show MDM2 Antibodies) oncogene (show RAB1A Antibodies) is a downstream target of Jmjd2c and may play an important role in Jmjd2c-mediated oncogenesis.
This gene is a member of the Jumonji domain 2 (JMJD2) family and encodes a protein with one JmjC domain, one JmjN domain, two PHD-type zinc fingers, and two Tudor domains. This nuclear protein functions as a trimethylation-specific demethylase, converting specific trimethylated histone residues to the dimethylated form. Chromosomal aberrations and increased transcriptional expression of this gene are associated with esophageal squamous cell carcinoma. Alternative splicing results in multiple transcript variants.
jumonji domain containing 2C
, lysine (K)-specific demethylase 4C
, jumonji domain containing 2c
, lysine-specific demethylase 4C
, lysine-specific demethylase 4C-like
, GASC-1 protein
, JmjC domain-containing histone demethylation protein 3C
, gene amplified in squamous cell carcinoma 1 protein
, jumonji domain-containing protein 2C
, tudor domain containing 14C
, gene amplified in squamous cell carcinoma 1
, jmjC domain-containing histone demethylation protein 3C